
This blog is a way of sharing, supporting and educating anyone dealing with a cancer-related illness about the options and treatments they have at their disposal.
You're browsing:
Home » About
IsoRay Medical™ was founded in
In March 2003 IsoRay Medical™ Inc. received clearance to market Cesium-131 from the Food and Drug Administration for the treatment of prostate, breast, liver, brain, head and neck cancers and other malignant disease. In October of 2004, a patient was first treated with Cesium-131 at the University of Washington Medical Center.
Beginning more than 40 years ago, Cesium-131 was the first choice over other radioactive medical isotopes, although scientific and economic considerations prevented its development. Once these hurdles were overcome, IsoRay Medical™, Inc. was formed to bring the new treatment tool to market.
The Cesium-131 Brachytherapy Seed offers physicians and their patients a new choice in isotope for the treatment of prostate cancer by combining a significantly shorter half-life with a high level of energy.
Treating prostate cancer using Cesium-131 is only the first step. The company expects to broaden treatment options with the development of protocols for the treatment of breast, liver, lung, pancreatic and other malignancies.